Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy
Piper Sandler downgraded Iovance Biotherapeutics Inc (NASDAQ:IOVA), citing the slow launch of Amtagvi (lifileucel), a prescription medicine used to treat adults with a type of skin cancer that cannot be removed surgically or has spread to other parts of the body called unresectable or metastatic melanoma.
The FDA approved the one-time, individualized T-cell therapy in February.
Amtagvi is made from surgically removed tumor. Tumor-derived T cells are grown in a manufacturing center.
Tumor tissue is sent to a manufacturing center to make Amtagvi. It takes about 34 days from the time tumor tissue is received at the manufacturing center until Amtagvi is available to be shipped back to the healthcare provider, but the time may …
Full story available on Benzinga.com
Related posts:
- Home Run To Homewrecker – Analyst Cautious On Homebuilders, Downgrades Key Players
- Aclaris Therapeutics’ ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
- Archer-Daniels-Midland’s Financial Figures ‘Are Too High,’ Analyst Downgrades Stock
- After 130% Surge, AMD Faces Uncertain Road Ahead: Top Analyst Says Chipmaker’s Future Shrouded In Doubt